If you are not happy with the results below please do another search
The FDA’s final rule for Direct-to-Consumer (DTC) Prescription Drug Advertisements became effective on May 20, implementing the statutory requirement that DTC advertisements for prescription drugs (Rx) in television or radio format must present the “major statement” on the drug’s most important risks, in a “clear, conspicuous, and neutral” manner.
The healthcare industry currently generates about 30 percent of the world’s data volume and that number is expanding rapidly, reaching an annual growth rate of 36 percent by next year. The life sciences are a major contributor to the expansion of the healthcare industry’s data, with a market growth rate of 11 percent up until 2032. In particular, drug development and monitoring continue to expand as the volume of information and variety of sources used in data collection increase. Organizations are now challenged with not only gathering and collecting data but also validating potential safety events.
This year’s class was drawn from an applicant pool of 4,627, underscoring both the popularity of the nextgenerATion program and the growing level of student interest in exploring careers in healthcare marketing and advertising.
Additional analyses from BridgeBio Pharma’s late-stage study show the oral drug candidate’s improved clinical outcomes in transthyretin amyloid cardiomyopathy patients.
As BioNTech struggles to establish its footing in a post-pandemic world, the biotech has secured $145 million from the Coalition for Epidemic Preparedness Innovations to expand its mRNA operations in Rwanda.
Yesterday Tris Pharma secured the FDA’s green light for Onyda XR, the first liquid non-stimulant nighttime treatment for attention deficit hyperactivity disorder in pediatric patients.
The company said it had begun a trial of its over-the-counter rapid test for detecting sexually transmitted infections (STI) such as chlamydia and gonorrhea, and aims to launch it by mid-2025.
The U.S. government is nearing an agreement to fund a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, the Financial Times reported on Thursday, as an H5N1 outbreak spreads through egg farms and among cattle herds.
As further sharp declines are expected for Humira, AbbVie has strategically pivoted to alternative immunology products to bolster its revenue streams. As such, two drugs, Skyrizi (risankizumab) and Rinvoq (upadacitinib), are emerging as key replacements. These products are forecast to collectively generate over $32 billion by 2030, enabling AbbVie to financially rebound and continue its position as a leading immunology player, says GlobalData.
Yesterday Amgen secured the FDA’s green light for the first interchangeable biosimilar to AstraZeneca’s Soliris to treat two rare diseases.